Gastric development of pancreatic acinar cell metaplasia after Vonoprazan therapy in rats
- 29 August 2023
- journal article
- research article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (12) , 9366-9372
Abstract
Background Vonoprazan is a new acid-suppressing drug that received FDA approval in 2022. It reversibly inhibits gastric acid secretion by competing with the potassium ions on the luminal surface of the parietal cells (potassium-competitive acid blockers or P-CABs). Vonoprazan has been on the market for a short time and there are many clinical trials to support its clinical application. However, medical experience and comprehensive clinical data is still limited, especially on how and if, gastric histology is altered due to therapy. Methods A 12-week experiment trial with 30 Wistar rats was to assess the presence of gastrointestinal morphologic abnormalities upon administration of omeprazole and vonoprazan. At six weeks of age, rats were randomly assigned to one of 5 groups: (1) saline as negative control group, (2) oral omeprazole (40 mg/kg), as positive control group, (3) oral omeprazole (40 mg/kg) for 4 weeks, proceeded by 8 weeks off omeprazole, (4) oral vonoprazan (4 mg/kg), as positive control group, and (5) oral vonoprazan (4 mg/kg) for 4 weeks, proceeded by 8 weeks off vonoprazan. Results We identified non-inflammatory alterations characterized by parietal (oxyntic) cell loss and chief (zymogen) cell hyperplasia and replacement by pancreatic acinar cell metaplasia (PACM). No significant abnormalities were identified in any other tissues in the hepatobiliary and gastrointestinal tracts. Conclusion PACM has been reported in gastric mucosa, at the esophagogastric junction, at the distal esophagus, and in Barrett esophagus. However, the pathogenesis of this entity is still unclear. Whereas some authors have suggested that PACM is an acquired process others have raised the possibility of PACM being congenital in nature. Our results suggest that the duration of vonoprazan administration at a dose of 4 mg/kg plays an important role in the development of PACM.Keywords
This publication has 39 references indexed in Scilit:
- Systematic Review: Patterns of Reflux-Induced Symptoms and Esophageal Endoscopic Findings in Large-Scale SurveysClinical Gastroenterology and Hepatology, 2012
- Prescribing Proton Pump InhibitorsDrugs, 2012
- Overutilization of proton-pump inhibitors: what the clinician needs to knowTherapeutic Advances in Gastroenterology, 2012
- Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse StomachGastroenterology, 2012
- A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in AnimalsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Development of Pancreatic Acinar Cell Metaplasia After Successful Administration of Omeprazole for 6 Months in RatsDigestive Diseases and Sciences, 2007
- Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junctionScandinavian Journal of Gastroenterology, 2005
- The gastric cardia in gastro-oesophageal diseaseJournal of Clinical Pathology, 2000
- Prevalence and Significance of Pancreatic Acinar Metaplasia at the Gastroesophageal JunctionAmerican Journal of Surgical Pathology, 1996
- Pancreatic Metaplasia in Barrettʼs Esophagus An Immunohistochemical StudyAmerican Journal of Surgical Pathology, 1995